Abstract
In recent years many studies have stressed the importance of using biological response modifiers (BRMs) in the treatment of different conditions of immune-impairment correlated with ageing, cancer and infectious diseases. In particular, the use of different BRMs in conjunction with conventional therapies has been extensively explored. Our studies have demonstrated that treatment with Thymosin α-1 and low doses of IFN or IL-2 exert powerful biological effects both in vitro and in vivo. They are highly effective in restoring cytotoxic activities in immunosuppression induced by tumors and/or cytostatic drugs. In addition, when combined with specific chemotherapy, they are able to induce a dramatic inhibition of tumor growth in both experimental models and in humans. Immunotherapeutic treatment also has an application in controlling infectious diseases, especially those occurring in the immune-compromised host. The advantage of using the combined immunotherapy treatment with antiviral drugs has been recently demonstrated by our group both in a murine experimental influenza model and in patients infected with HBV, HCV and HIV.
| Original language | English |
|---|---|
| Pages (from-to) | 103-116 |
| Number of pages | 14 |
| Journal | Mechanisms of Ageing and Development |
| Volume | 96 |
| Issue number | 1-3 |
| DOIs | |
| Publication status | Published - Jun 1997 |
Fingerprint
Keywords
- Biological response modifiers (BRMs)
- Infectious diseases
- Thymosin α-1
ASJC Scopus subject areas
- Ageing
- Biochemistry
- Developmental Biology
- Developmental Neuroscience
Cite this
Combination therapy with BRMs in cancer and infectious diseases. / Garaci, Enrico; Pica, Francesca; Rasi, Guido; Palamara, Anna T.; Favalli, Cartesio.
In: Mechanisms of Ageing and Development, Vol. 96, No. 1-3, 06.1997, p. 103-116.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Combination therapy with BRMs in cancer and infectious diseases
AU - Garaci, Enrico
AU - Pica, Francesca
AU - Rasi, Guido
AU - Palamara, Anna T.
AU - Favalli, Cartesio
PY - 1997/6
Y1 - 1997/6
N2 - In recent years many studies have stressed the importance of using biological response modifiers (BRMs) in the treatment of different conditions of immune-impairment correlated with ageing, cancer and infectious diseases. In particular, the use of different BRMs in conjunction with conventional therapies has been extensively explored. Our studies have demonstrated that treatment with Thymosin α-1 and low doses of IFN or IL-2 exert powerful biological effects both in vitro and in vivo. They are highly effective in restoring cytotoxic activities in immunosuppression induced by tumors and/or cytostatic drugs. In addition, when combined with specific chemotherapy, they are able to induce a dramatic inhibition of tumor growth in both experimental models and in humans. Immunotherapeutic treatment also has an application in controlling infectious diseases, especially those occurring in the immune-compromised host. The advantage of using the combined immunotherapy treatment with antiviral drugs has been recently demonstrated by our group both in a murine experimental influenza model and in patients infected with HBV, HCV and HIV.
AB - In recent years many studies have stressed the importance of using biological response modifiers (BRMs) in the treatment of different conditions of immune-impairment correlated with ageing, cancer and infectious diseases. In particular, the use of different BRMs in conjunction with conventional therapies has been extensively explored. Our studies have demonstrated that treatment with Thymosin α-1 and low doses of IFN or IL-2 exert powerful biological effects both in vitro and in vivo. They are highly effective in restoring cytotoxic activities in immunosuppression induced by tumors and/or cytostatic drugs. In addition, when combined with specific chemotherapy, they are able to induce a dramatic inhibition of tumor growth in both experimental models and in humans. Immunotherapeutic treatment also has an application in controlling infectious diseases, especially those occurring in the immune-compromised host. The advantage of using the combined immunotherapy treatment with antiviral drugs has been recently demonstrated by our group both in a murine experimental influenza model and in patients infected with HBV, HCV and HIV.
KW - Biological response modifiers (BRMs)
KW - Infectious diseases
KW - Thymosin α-1
UR - http://www.scopus.com/inward/record.url?scp=0030922206&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0030922206&partnerID=8YFLogxK
U2 - 10.1016/S0047-6374(97)01895-2
DO - 10.1016/S0047-6374(97)01895-2
M3 - Article
C2 - 9223114
AN - SCOPUS:0030922206
VL - 96
SP - 103
EP - 116
JO - Mechanisms of Ageing and Development
JF - Mechanisms of Ageing and Development
SN - 0047-6374
IS - 1-3
ER -